Current stock page

Stock Analysis

Novavax, Inc. (NVAX) Stock Analysis

Novavax, Inc. (NVAX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

NVAX Stock Analysis Summary

Novavax, Inc. (NVAX) currently has an AIQ Score of —, indicating a — setup. Momentum is the strongest factor at 77/100. Risk is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

NVAX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$8.53
AIQ Score—
Overall ViewUnavailable
Technical Analysis ConsensusStrong Sell
Market Cap$1.41B
P/E Ratio (TTM)-18.53
Forward P/E—
EPS (Q3 FY2026)-$0.19
Revenue (Q3 FY2026)$68.3M
Dividend Yield (TTM)0.00%
Beta2.12
Volume4.64M
52-week range$6.20-$13.39
RSI 1437.64
50-Day SMA$10.54
200-Day SMA$9.33
Analyst Price Target$8.00
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

NVAXNovavax, Inc.

Healthcare / Biotechnology

$8.53−$0.23 (−2.68%)

Latest quote

  • Momentum
    77
  • Value
    —
  • Quality
    62
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

NVAX Stock Analysis Summary

Novavax, Inc. (NVAX) currently has an AIQ Score of —, indicating a — setup. Momentum is the strongest factor at 77/100. Risk resilience is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Unavailable

In a — regime, NVAX has AIQ Score of — with Momentum base of 77/100 and fading Risk resilience at 38/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (77/100) leads while Risk resilience (38/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.68% stock move · NVAX classified in Biotechnology.

Current Evidence

—NVAX is in a — AIQ regime; Momentum is the strongest visible factor at 77/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is NVAX Bullish or Bearish Right Now?

NVAX currently has a unavailable overall setup. Momentum is the strongest factor at 77/100, while Risk Resilience is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 77/100.
Bear Case
  • - Risk Resilience is weak at 38/100.
  • - Price is -8.66% below its 200-day SMA.
  • - Analyst target implies -6.16% downside from the latest quote.
  • - Technical consensus has more sell votes than buy votes (37 vs 6).

Current Consensus

NVAX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. NVAX's 14-day RSI is 37.64, which places the stock in a weaker momentum range. NVAX's beta is 2.12, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in NVAX?

The largest recent change in NVAX is Quality moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
—
Momentum
+1.0
Quality
+2.0
Risk
-1.0

What Would Change the NVAX Outlook?

The current unavailable outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

NVAX Decision Framework

Public evidence layers, setup checks, and risk context for Novavax, Inc..

Novavax, Inc. (NVAX) Stock Analysis

Novavax, Inc. has an AIQ Score of — in a — regime. Momentum is strongest at 77/100. Beta is 2.12, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextNVAX is in a — AIQ regime with score —.
Signal ConflictThe primary conflict is that momentum leads at 77/100 while risk lags at 38/100.
Factor EvidenceMomentum 77/100 · Quality 62/100 · Risk 38/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 77/100.

TimingPass

Momentum is 77/100 and RSI (14) is 37.6.

Regime fitWait

NVAX is in a — regime at —.

Risk controlFail

Risk factor is 38/100 with beta 2.12 and annual volatility 73.62%.

ConflictWait

Current conflict: momentum leads at 77/100 while risk lags at 38/100.

AIQ Score
—
Price
$8.53
Beta
2.12
RSI (14)
37.6

NVAX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

NVAX Fundamentals

NVAX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$68.3M
Net income
-$31.38M
Free cash flow
-$95.26M
View full NVAX fundamental analysis

NVAX Technical Analysis

NVAX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
37.64
Price vs SMA-50
-19.09%
View full NVAX technical analysis

NVAX Stock Catalysts

Track NVAX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$8.00
News items
4
View NVAX earnings and stock catalysts

NVAX Dividend Analysis

NVAX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View NVAX dividend history and analysis

NVAX Financial Data

NVAX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$68.3M
EPS
-$0.19
Periods
8
View NVAX financials

NVAX Risk Analysis

NVAX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.12
Risk score
38/100
1Y volatility
73.62%
View NVAX risk analysis

NVAX Stock News

NVAX stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read NVAX stock news

NVAX vs Biotechnology Peers

Current peer cohort: NVAX · OCUL · OMER · ONC · ORKA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
NVAX
Current stock
——77/10038/1000.5673.62%Current
OCUL
Ocular Therapeutix, Inc.
38/10041/10034/10036/100-0.4576.10%NVAX vs OCUL
OMER
Omeros Corporation
64/10073/10079/10033/1001.36110.84%NVAX vs OMER
ONC
BeOne Medicines AG
80/10071/10091/10072/1000.4234.16%NVAX vs ONC
ORKA
Oruka Therapeutics, Inc.
77/100—81/10053/1002.2969.09%NVAX vs ORKA
Pairwise Compare links: OCUL · OMER · ONC · ORKANVAX vs OCULNVAX vs OMERNVAX vs ONCNVAX vs ORKACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a NVAX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for NVAX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-18.53
As of Nov 13, 2026
Revenue growth
-3.05%
Gross margin
77.25%
Current debt / equity
-1.36
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$68.3M
Quarter net income
-$31.38M
Quarter free cash flow
-$95.26M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
37.64
MACD
-0.37

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
38/100
Beta
2.12
Annual volatility
73.62%
Max drawdown
-34.58%

NVAX Stock FAQ

What is NVAX stock price today?

Novavax, Inc.'s current stock price is $8.53. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is NVAX bullish or bearish right now?

NVAX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is NVAX's market cap?

NVAX's market cap is $1.41B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is NVAX's current P/E ratio?

NVAX's current P/E ratio is -18.53 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is NVAX's RSI?

NVAX's 14-day RSI is 37.64 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is NVAX above its 50-day and 200-day moving averages?

NVAX is -19.09% from its 50-day SMA and -8.66% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is NVAX's next earnings date?

NVAX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does NVAX pay a dividend?

NVAX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.